THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 84 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $702,983 | -17.3% | 81,458 | -0.9% | 0.09% | -23.9% |
| Q2 2023 | $850,335 | -4.8% | 82,158 | -0.2% | 0.12% | -3.3% |
| Q1 2023 | $893,617 | -3.3% | 82,361 | +0.0% | 0.12% | -19.3% |
| Q4 2022 | $923,653 | +11.6% | 82,322 | +0.8% | 0.15% | +20.0% |
| Q3 2022 | $828,000 | -41.5% | 81,658 | -47.7% | 0.12% | 0.0% |
| Q2 2022 | $1,415,000 | -23.2% | 156,131 | -19.0% | 0.12% | -21.4% |
| Q1 2022 | $1,842,000 | +49.6% | 192,701 | +73.0% | 0.16% | +69.1% |
| Q4 2021 | $1,231,000 | +27.0% | 111,379 | +104.3% | 0.09% | +44.6% |
| Q4 2020 | $969,000 | -0.8% | 54,522 | -17.5% | 0.06% | 0.0% |
| Q3 2020 | $977,000 | +89.0% | 66,061 | +168.4% | 0.06% | +85.7% |
| Q2 2020 | $517,000 | +166.5% | 24,614 | +39.2% | 0.04% | +775.0% |
| Q3 2015 | $194,000 | -65.3% | 17,683 | -58.8% | 0.00% | -73.3% |
| Q2 2015 | $559,000 | +96.8% | 42,927 | +161.9% | 0.02% | +114.3% |
| Q1 2015 | $284,000 | – | 16,393 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |